Abstract:Background and aim: The therapeutic effect of pegylated interferon (peg-IFN)-alpha-2a combination with ribavirin on patients with chronic hepatitis C virus (HCV) infection is dependent on the rapidity of the virological response. The aim of this study was to investigate the predictive value of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) in HCV patients treated with peg-IFN-alpha-2a and ribavirin.Methods: The HCV genotypes of 105 patients with chronic hepatitis C were detected by enzyme-immunoassay. Patients received subcutaneous 180 mu g peg-IFN-alpha-2a once weekly plus daily ribavirin. Patients with genotype 1 were treated for 48 weeks and patients with genotype 2 or 3 were treated for 24 weeks. HCV RNA was assessed by qualitative PCR at pretreatment, at weeks 4 and 12 during treatment, and at week 24 of follow-up. Virological response rates at different weeks were investigated, with RVR defined as serum HCV RNA undetectable after 4 weeks and EVR defined as HCV RNA either undetectable or decrease by >= 2 log(10) after 12 weeks. The effects of virological response rates at different weeks on SVR were analyzed.Results: Of the 105 patients, 44 (41.9%) were genotype 1, 46 (43.8%) were genotype 2, and 15 (14.3%) were genotype 3. RVR rates (19.5%) of patients with genotype 1 were significantly lower than those (60.7%) of genotype 2 or 3 (chi(2) = 16.836, P = 0.000); and EVR rates (73.2%) of patients with genotype 1 were significantly lower than those (96.7%) of genotype 2 or 3 (chi(2) = 12.220, P = 0.000). The SVR rates (86.7%) of patients who had achieved RVR were significantly higher than those (43.9%) of patients who had not achieved RVR (chi(2) = 19.713, P = 0.000). The positive predictive value of RVR in all patients was higher than that of EVR, but there was no significant difference between RVR and EVR. The negative predictive value of RVR in all patients or with genotype 1 was significantly lower than that of EVR. In univariate analysis, HCV RNA level (P = 0.014), genotype (P = 0.001), RVR (P = 0.000) and EVR (P = 0.000) were associated with effect of treatment. However, in stepwise regression analysis, the independent factors associated with effect of antiviral therapy were RVR (OR = 6.501, P = 0.001), EVR (OR = 2.776, P = 0.003) and genotype (OR = 3.061, P = 0.024).Conclusions: The RVR and EVR rates of patients with genotype 1 were significantly lower than those of patients with genotype 2 or 3. RVR had a similar predictive value as EVR on SVR. Genotype, HCV RNA level, RVR and EVR were associated with SVR. Genotype, RVR and EVR were independent factors for predicting the effect of antiviral therapy.

Mutations in the NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated interferon alpha-2a and ribavirin combination therapy

Amino Acid Sequence Analysis in Patients with Chronic HCV Genotype 1b Infection During Pegylated Interferon-Α2a and Ribavirin Therapy.

What are the limits of efficacy for immunotherapy against hepatocellular carcinoma and its clinical availability

Association of Single Nucleotide Polymorphisms in Interferon Signaling Pathway Genes and Interferon-Stimulated Genes with the Response to Interferon Therapy for Chronic Hepatitis C

Correlationship Between HCV-1b Gene Mutations Genotype and Therapeutic Effects of Interferon/ribavirin in Patients with Chronic HCV-1b Infection

Association Between NS5A Gene Sequence and Response to Interferon Therapy in Chronic Hepatitis C Patients in Shanghai

Association of Genetic Variations in GNB1 with Response to Peginterferon Plus Ribavirin Therapy for Chronic Hepatitis C in a Chinese Population in Taiwan

Interaction Between Variability of Nonstructural Gene5b of Hepatitis C Virus and Interferon Therapy

Prediction of Response to Pegylated-Interferon-α and Ribavirin Therapy in Chinese Patients Infected with Different Hepatitis C Virus Genotype

Changes of Inflammatory Cytokines/chemokines During Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin Therapy for Patients with Genotype 1b Hepatitis C Infection

Predictive Value Of Rapid Virological Response And Early Virological Response On Sustained Virological Response In Hcv Patients Treated With Pegylated Interferon Alpha-2a And Ribavirin

Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C

Association between polymorphisms and interferon/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study.

Predictive Value of Virological Response on Relapsing Rate and Its Factors in Chronic Hepatitis C Genotype 1 Patients Treated by Pegylated Interferon Α-2A Plus Ribavirin

A study on relationship between genotyping of hepatitis C virus and therapeutic effects

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients

The Association of LMP7 and TAP2 Gene Polymorphisms with Treatment Response to Interferon/ribavirin in Patients with Genotype 1 Chronic Hepatitis C.

Impact of Virus Genotype on Interferon Treatment of Patients with Chronic Hepatitis C: a Multicenter Controlled Study.

Viral Sequence Evolution in Chinese Genotype 1b Chronic Hepatitis C Patients Experiencing Unsuccessful Interferon Treatment

1173 IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5B NON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJOR HCV GENOTYPES

Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients.